Patients with worsening heart failure who received colchicine, a common gout medication, had a survival rate of 97.9% compared with a 93.5% survival rate for patients who did not take colchicine.
Colchicine, a common gout medication, dramatically increased the survival rates of patients with worsening heart failure who were hospitalized, according to a recent University of Virginia (UVA) Health study. In individuals with an accumulation of cholesterol in their arteries, the researchers think colchicine might also lower the risk for heart attack and stroke.
More than 1,000 patients who were hospitalized at the University of Virginia Medical Center between March 2011 and February 2020 due to worsening heart failure had their records examined. Patients who took colchicine for a gout flare had a survival rate of 97.9%, as opposed to patients who did not receive colchicine, who had a survival rate of 93.5%.
Comments are closed.